| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/15/2005 | US6855685 Anti-cancer agent |
| 02/15/2005 | US6855684 Compound B as angiogenic agent in combination with human growth factors |
| 02/15/2005 | US6855546 Reducing binding of ubiquitin-proteasome system to cell surface receptor via peptide mimetics; for treating diabetes, glandular and muscle disorders |
| 02/15/2005 | US6855543 Expression vector coding transmembrane region and an apoptosis inducing domain for treating cancer and/or autoimmune diseases; gene therapy |
| 02/15/2005 | US6855532 Gene therapy; drug screening |
| 02/15/2005 | US6855530 Polypeptides; prevention gene expression |
| 02/15/2005 | US6855528 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 02/15/2005 | US6855520 Cell volume-regulated human kinase h-sgk |
| 02/15/2005 | US6855517 Compositions and methods relating to breast specific genes and proteins |
| 02/15/2005 | US6855510 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 02/15/2005 | US6855365 Recombinant bacterial phytases and uses thereof |
| 02/15/2005 | US6855331 Sustained release hydrophobic bioactive PLGA microspheres |
| 02/15/2005 | US6855323 Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A |
| 02/15/2005 | US6855321 Polyepitope carrier protein |
| 02/15/2005 | US6855317 Immunological herpes simplex virus antigens and methods for use thereof |
| 02/15/2005 | US6855315 Kits for detecting swine infertility and respiratory syndrome (SIRS) virus |
| 02/15/2005 | US6854731 Method and device for playing an improved game of blackjack |
| 02/15/2005 | US6854468 Treatment of subnormal bone mineral density |
| 02/15/2005 | CA2405466C Method for synthesis of n-[(s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril |
| 02/15/2005 | CA2119562C Method and compositions for the treatment of cerebral palsy |
| 02/12/2005 | CA2436979A1 Methods for preventing neurological events |
| 02/10/2005 | WO2005012542A1 Casein hydrolyzate, process for producing the same and use thereof |
| 02/10/2005 | WO2005012541A1 Method for producing cyclic molecules |
| 02/10/2005 | WO2005012525A1 Short interfering rna as an antiviral agent for hepatitis c |
| 02/10/2005 | WO2005012524A1 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer |
| 02/10/2005 | WO2005012513A1 Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regenaration |
| 02/10/2005 | WO2005012489A2 Targeting endothelium for tissue-specific delivery of agents |
| 02/10/2005 | WO2005012485A2 Methods for treating diabetes and related disorders using pde10a inhibitors |
| 02/10/2005 | WO2005012363A1 Targeting inflammation inducer |
| 02/10/2005 | WO2005012357A1 Bcl-2 splicing variants |
| 02/10/2005 | WO2005012355A1 Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis |
| 02/10/2005 | WO2005012354A1 Method for extending the half-life of fviii |
| 02/10/2005 | WO2005012352A1 SOLUBLE HUMAN INTERLEUKIN 18 RECEPTOR-α, METHOD OF ASSAYING THE SAME, ASSAY KIT AND MEDICINAL COMPOSITION |
| 02/10/2005 | WO2005012350A2 Epha2 t-cell epitope agonists and uses therefor |
| 02/10/2005 | WO2005012348A2 Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
| 02/10/2005 | WO2005012347A2 Novel insulin derivatives |
| 02/10/2005 | WO2005012346A1 Long lasting insulin derivatives and methods thereof |
| 02/10/2005 | WO2005012338A1 Antigenic peptides of sars coronavirus and uses thereof |
| 02/10/2005 | WO2005012336A2 Uranium-chelating peptides and uses thereof |
| 02/10/2005 | WO2005012335A1 Imaging agents |
| 02/10/2005 | WO2005012334A1 Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food |
| 02/10/2005 | WO2005012333A2 Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof |
| 02/10/2005 | WO2005012332A1 Spatially-defined macrocycles incorporating peptide bond surrogates |
| 02/10/2005 | WO2005012331A1 Spatially-defined macrocyclic compounds useful for drug discovery |
| 02/10/2005 | WO2005012329A2 Kinase and phosphatase assays |
| 02/10/2005 | WO2005012328A2 Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof |
| 02/10/2005 | WO2005012305A2 Tricyclic parp inhibitors |
| 02/10/2005 | WO2005012280A1 Alkynyl aryl carboxamides |
| 02/10/2005 | WO2005011742A1 Method of treating hepatocellular carcinoma |
| 02/10/2005 | WO2005011734A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 02/10/2005 | WO2005011728A2 Use of soluble cd164 in inflammatory and/or autoimmune disorders |
| 02/10/2005 | WO2005011726A1 Use of follicle stimulating hormone for reduction of spermatozoa chromosomal aberration in males |
| 02/10/2005 | WO2005011725A2 Anti-angiogenetic agent and its use, in particular in cancer treatment |
| 02/10/2005 | WO2005011724A1 A method of producing an anticoagulation effect |
| 02/10/2005 | WO2005011723A1 Preventive and/or remedy for hematopoietic tumor |
| 02/10/2005 | WO2005011722A2 Use of vegf-c or vegf-d in reconstructive surgery |
| 02/10/2005 | WO2005011721A2 Use of a pak inhibitor for the treatment of a joint disease |
| 02/10/2005 | WO2005011715A1 Viral vectors |
| 02/10/2005 | WO2005011689A2 Treatment of inflamed joints |
| 02/10/2005 | WO2005011640A2 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 02/10/2005 | WO2005011620A2 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| 02/10/2005 | WO2005011612A2 Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism |
| 02/10/2005 | WO2005011607A2 Treatment of cancers expressing p95 erbb2 |
| 02/10/2005 | WO2005011605A2 Combination therapies for multiple sclerosis |
| 02/10/2005 | WO2005011584A2 Decorin proteoglycan inhibitor of fibrinogen blood clotting |
| 02/10/2005 | WO2005004893A3 Inhibition of stress-induced ligand-dependent egfr activation |
| 02/10/2005 | WO2004111088A3 Angiogenic factor and inhibitors thereof |
| 02/10/2005 | WO2004107618A3 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
| 02/10/2005 | WO2004104030A3 Peptides modulating the activity of the engrailed transcription factor |
| 02/10/2005 | WO2004097421A3 Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
| 02/10/2005 | WO2004094462A3 Methods of peptide preparation |
| 02/10/2005 | WO2004093903A3 Methods and compositions for immunomodulation using cd1 antigens |
| 02/10/2005 | WO2004092383A3 RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/10/2005 | WO2004089335A3 Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| 02/10/2005 | WO2004083446A3 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 02/10/2005 | WO2004073652A3 Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| 02/10/2005 | WO2004070034A3 Oligonucleotides directed against a survivin gene and use thereof |
| 02/10/2005 | WO2004058943A3 Device and process for the preparation of autologous thrombin serum |
| 02/10/2005 | WO2004058188A3 Vaccine compositions and methods |
| 02/10/2005 | WO2004048526A3 MODULATION OF HIF1α AND HIF2α EXPRESSION |
| 02/10/2005 | WO2004043332A3 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| 02/10/2005 | WO2004039830A3 Bioactivation of particles |
| 02/10/2005 | WO2004016647A3 Fragments of proinsulin c-peptide |
| 02/10/2005 | WO2003100031A3 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
| 02/10/2005 | WO2003099338A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 02/10/2005 | WO2003086175A8 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/10/2005 | WO2003083079A9 Bone generation by gene therapy |
| 02/10/2005 | WO2003072731A3 STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
| 02/10/2005 | WO2003068943A3 Secreted proteins |
| 02/10/2005 | WO2003063760A3 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| 02/10/2005 | WO2003062197A3 Nek2 inhibitors |
| 02/10/2005 | WO2002020718A3 Osteoclast-associated receptor |
| 02/10/2005 | WO2000024869A9 Methods for modulating cell fusion |
| 02/10/2005 | US20050033522 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033051 treatment of RNA viral infections such as HCV, HBV, small pox, Ebola, polio, West Nile, Coxsackie A and B, Rhino, and Echo viral infection using modified nucleotides; viricides |
| 02/10/2005 | US20050033035 Mutants of igf binding proteins and methods of production of antagonists thereof |
| 02/10/2005 | US20050033032 NIMA interacting proteins |
| 02/10/2005 | US20050033026 Immunoconjugates for the treatment of tumours |
| 02/10/2005 | US20050033025 Human papilloma viral proteins fragments for use in generating immunoglobullins for treatment and prevention infection; immunotherapeutics and diagnostice; viricides |